The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and tolerability of T-SIGn vectors when administered using “flat” versus “low-high-high” (LHH) dosing regimens.
 
Thomas Lillie
Employment - PsiOxus Therapeutics
Leadership - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics
 
Lee S. Rosen
Research Funding - Bayer (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Rgenix (Inst)
 
David Krige
Employment - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics
 
Minesh Patel
Employment - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics
 
Isabel Prieto González-Albo
Employment - PsiOxus Therapeutics
 
Jo Carter
Employment - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics
 
Behnaz Ravanfar
Employment - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics
 
Vladimir Evilevitch
Employment - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics
 
Aung Naing
Consulting or Advisory Role - CSL Behring (I); CytomX Therapeutics; Deka Biosciences; Genome & Company; Horizon Pharma (I); Kymab; Novartis; OncoSec; Pharming NV (I); STCube Pharmaceuticals Inc.; Takeda (I)
Research Funding - Amplimmune; Arcus Biosciences; ARMO BioSciences; Atterocor; Baxalta (I); BioNTech SE; Bristol-Myers Squibb; Calithera Biosciences; Chao Physician-Scientist Awards (I); CytomX Therapeutics; EMD Serono; Healios; Immune Deficiency Foundation (I); ImmuneOncia; Incyte; Jeffrey Modell Foundation (I); Karyopharm Therapeutics; Kymab; Lilly; MedImmune; Merck; Monopteros Therapeutics; NCI; NeoImmuneTech; Neon Therapeutics; Novartis; Pfizer; PsiOxus Therapeutics; Regeneron; Seven and Eight Biopharmaceuticals; Sotio; Surface Oncology; TopAlliance BioSciences Inc
Travel, Accommodations, Expenses - ARMO BioSciences